Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors - Lemech, Charlotte; Dredge, Keith; Bampton, Darryn; Hammond, Edward; Clouston, Andrew; Waterhouse, Nigel J; Stanley, Amanda C; Leveque-El Mouttie, Lucie; Chojnowski, Grace M; Haydon, Andrew; Pavlakis, Nick; Burge, Matthew; et al. (Journal for immunotherapy of cancer, 2023)
Keywords: Adenocarcinoma - pathology; Angiogenesis Inhibitors - therapeutic use; Antibodies; Anticoagulants; Biomarkers; Cancer; Cancer therapies; Chemokine CXCL10; Clinical/Translational Cancer Immunotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; Drug dosages; Drug Therapy, Combination; FDA approval; Humans; Immunomodulation; Immunotherapy; Ligands; Lymphocyte Activation; Metastasis; Microsatellite Repeats; Monoclonal antibodies; Nivolumab - pharmacology; Nivolumab - therapeutic use; Pancreatic cancer; Pancreatic Neoplasms; Radiation; Targeted cancer therapy; Toll-Like Receptor 9; Tumors; Australia; New South Wales Australia; Drug Therapy, Combination; Immunomodulation; Lymphocyte Activation; Immunotherapy